Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Boer

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Current Opinion in Drug Discovery & Development|February 1, 2006
The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolismMichael B Fisher, Kirk R Henne, Jason Boer
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 28, 2010
Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implicationsSharon Diamond, Jason Boer, Thomas P Maduskuie, et al.
ACS Medicinal Chemistry Letters|November 20, 2020
Biotransformation: Impact and Application of Metabolism in Drug DiscoveryJulia Shanu-Wilson, Liam Evans, Stephen Wrigley, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 12, 2017
In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug InteractionsQiang Zhang, Yan Zhang, Jason Boer, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 27, 2016
Roles of UGT, P450, and Gut Microbiota in the Metabolism of Epacadostat in HumansJason Boer, Ruth Young-Sciame, Fiona Lee, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 27, 2014
The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathyQiang Zhang, Yan Zhang, Sharon Diamond, et al.
Current Drug Metabolism|June 25, 2005
A comprehensive listing of bioactivation pathways of organic functional groupsAmit S Kalgutkar, Iain Gardner, R Scott Obach, et al.
Bioorganic & Medicinal Chemistry Letters|May 12, 2009
Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activityDaniel P Walker, Michael P Zawistoski, Molly A McGlynn, et al.
Clinical Pharmacology and Therapeutics|December 11, 2023
Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working GroupWenkui Li, Faye Vazvaei-Smith, Gordon Dear, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2011
A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3Xiangdong Liu, Qian Wang, Gengjie Yang, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Current Opinion in Drug Discovery & Development|February 1, 2006
The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolismMichael B Fisher, Kirk R Henne, Jason Boer
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 28, 2010
Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implicationsSharon Diamond, Jason Boer, Thomas P Maduskuie, et al.
ACS Medicinal Chemistry Letters|November 20, 2020
Biotransformation: Impact and Application of Metabolism in Drug DiscoveryJulia Shanu-Wilson, Liam Evans, Stephen Wrigley, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 12, 2017
In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug InteractionsQiang Zhang, Yan Zhang, Jason Boer, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 27, 2016
Roles of UGT, P450, and Gut Microbiota in the Metabolism of Epacadostat in HumansJason Boer, Ruth Young-Sciame, Fiona Lee, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 27, 2014
The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathyQiang Zhang, Yan Zhang, Sharon Diamond, et al.
Current Drug Metabolism|June 25, 2005
A comprehensive listing of bioactivation pathways of organic functional groupsAmit S Kalgutkar, Iain Gardner, R Scott Obach, et al.
Bioorganic & Medicinal Chemistry Letters|May 12, 2009
Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activityDaniel P Walker, Michael P Zawistoski, Molly A McGlynn, et al.
Clinical Pharmacology and Therapeutics|December 11, 2023
Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working GroupWenkui Li, Faye Vazvaei-Smith, Gordon Dear, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2011
A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3Xiangdong Liu, Qian Wang, Gengjie Yang, et al.
Pageof 2